ABUS vs SNPS · P/E 5.4, rev $6.2M vs P/E 63, rev $7.05B
Arbutus Biopharma Corp (ABUS) versus Synopsys Inc (SNPS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Synopsys Inc (SNPS) is a software - infrastructure company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported SNPS revenue for 2025-10-31 was $7.05B. Net income was $1.33B. Revenue was up 15.1% from 2024-10-31 to 2025-10-31. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
Not investment advice. Open the ABUS and SNPS stock pages for the full models.
Not investment advice.